The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Renosen Pharmaceuticals Pvt Ltd
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Renosen Pharmaceuticals Pvt Ltd, part of the promoter/promoter group of Senores Pharmaceuticals Ltd, has acquired 4,000 equity shares through the open market on December 17, 2025. This represents 0.01% of the company's total share capital. Following this acquisition, Renosen's total holding in Senores Pharmaceuticals has increased from 27,08,719 shares (5.88%) to 27,12,719 shares (5.89%). The acquisition was disclosed under Regulation 29(2) of the SEBI Takeover Regulations.
This is a minor incremental share purchase by a promoter group entity, signalling continued promoter confidence in the company. However, given the very small size of the acquisition, it is unlikely to have any material impact on the stock price or shareholder value.